

[Skip to main content](#)

Desmopressin Acetate Tablets (DDAVP)

??? ??????: 30 ?????2/????? 2017

Infrequently, large doses of the intranasal formulations of DDAVP (desmopressin acetate tablets) and DDAVP (desmopressin acetate tablets) Injection have produced transient headache, nausea, flushing and mild abdominal cramps. These symptoms have disappeared with reduction in dosage.

DDAVP In long-term clinical studies in which patients with diabetes insipidus were followed for periods up to 44 months of **Central Diabetes Insipidus:** therapy, transient increases in AST (SGOT) no higher than 1.5 times the upper limit of normal were occasionally observed. **(desmopressin acetate tablets) Tablet**
DDAVP (desmopressin acetate tablets) Tablets. Elevated AST (SGOT) returned to the normal range despite continued use of

DDAVP (desmopressin acetate tablets) The only adverse event occurring in ? 3% of patients in controlled clinical trials with **Primary Nocturnal Enuresis:** that was probably, possibly, or remotely related to study drug was headache (4% DDAVP (desmopressin acetate tablets) , 3% placebo). **Tablets**

The following adverse events have been reported; however their relationship to DDAVP (desmopressin acetate tablets) has not been established: abnormal **Other:** thinking, diarrhea, and edema-weight gain.

for the possibility of water intoxication and hyponatremia. **WARNINGS** See

There have been rare reports of hyponatremic convulsions associated with concomitant use with the following medications: oxybutinin and **Post Marketing:** imipramine.